Skip to main content

Table 2 Clinical characteristics at initiation of 7 bDMARDs and tofacitinib (bDMARDs-switched cases)

From: Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study

Variable ABT (n = 273) ADA (n = 162) CZP (n = 91) ETN (n = 240) GLM (n = 250) IFX (n = 74) TCZ (n = 487) TOF (n = 101)
Age (years) 61.5 ± 13.2 55.4 ± 14.8 54.1 ± 15.4 55.5 ± 15.7 60.5 ± 14.6 53.5 ± 12.6 58.1 ± 14.1 59.7 ± 13.6
Female sex (%) 81.3 87.7 85.7 82.1 88.0 79.5 82.5 77.2
Disease duration (years) 11.2 ± 9.3 9.7 ± 9.0 9.9 ± 9.0 9.4 ± 8.1 12.0 ± 10.2 10.9 ± 16.0 10.0 ± 8.9 11.0 ± 8.6
RF positivity (%) 77.8 78.2 77.2 75.6 78.1 72.7 79.9 80.0
ACPA positivity (%) 84.4 80.9 84.8 86.5 82.9 82.4 83.3 73.3
DAS28-ESR 4.3 ± 1.3 3.9 ± 1.1 4.4 ± 1.5 4.1 ± 1.4 4.0 ± 1.4 4.0 ± 1.6 4.4 ± 1.4 4.3 ± 1.3
CDAI 14.7 ± 9.5 11.9 ± 8.8 16.3 ± 10.8 13.7 ± 10.0 14.6 ± 10.2 18.9 ± 13.0 16.3 ± 10.3 19.3 ± 11.3
HAQ-DI 1.1 ± 0.8 0.8 ± 0.7 1.2 ± 0.9 0.9 ± 0.8 1.1 ± 0.8 1.0 ± 1.0 1.2 ± 0.8 1.0 ± 0.8
PSL usage (%) 55.1 44.1 40.7 47.0 46.0 42.5 52.2 54.5
PSL dose (mg/day) 6.4 ± 4.1 5.9 ± 4.3 4.9 ± 2.9 5.6 ± 3.8 5.1 ± 3.5 5.6 ± 3.1 6.1 ± 3.9 4.1 ± 3.1
MTX usage (%) 47.8 57.1 62.6 50.0 66.1 100.0 54.9 51.5
MTX dose (mg/week) 8.4 ± 3.0 8.0 ± 2.9 8.4 ± 3.1 8.3 ± 2.7 8.0 ± 3.1 8.7 ± 2.8 8.4 ± 3.1 9.0 ± 3.3
Starting date 2001–2009 (%) 0.0 25.3 0.0 27.5 0.0 20.3 10.9 0.0
Starting date 2010–2013 (%) 43.2 49.4 26.4 37.5 48.8 51.4 45.8 2.0
Starting date 2014–2019 (%) 56.8 25.3 73.6 35.0 51.2 28.4 43.3 98.0
2nd bio or TOF (%) 54.6 75.9 41.8 74.6 58.8 70.3 57.3 31.7
≥ 3rd bio or TOF (%) 45.4 24.1 58.2 25.4 41.2 29.7 42.7 68.3
  1. Values are mean ± standard deviation or percentages. bDMARDs biological disease-modifying antirheumatic drugs, ABT abatacept, ADA adalimumab, CZP certolizumab pegol, ETN etanercept, GLM golimumab, IFX infliximab, TCZ tocilizumab, TOF tofacitinib, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, DAS28-ESR Disease Activity Score in 28 joints using erythrocyte sedimentation rate, CDAI clinical disease activity index, HAQ-DI Health Assessment Questionnaire disability index, PSL prednisolone, MTX methotrexate, bio biologic agent